Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Treatment of osteoporosis in women intolerant of oral bisphosphonates.

Aspray TJ, Francis RM.

Maturitas. 2012 Jan;71(1):76-8. doi: 10.1016/j.maturitas.2011.10.005. Epub 2011 Nov 10. Review.

PMID:
22079368
2.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
3.

Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.

Gallacher SJ, Dixon T.

Calcif Tissue Int. 2010 Dec;87(6):469-84. doi: 10.1007/s00223-010-9420-x. Epub 2010 Sep 26. Review.

PMID:
20872215
4.

Developments in the pharmacotherapeutic management of osteoporosis.

Close P, Neuprez A, Reginster JY.

Expert Opin Pharmacother. 2006 Aug;7(12):1603-15. Review.

PMID:
16872263
5.
6.

Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.

Cole RE.

Postgrad Med. 2011 Mar;123(2):131-44. doi: 10.3810/pgm.2011.03.2271. Review.

PMID:
21474901
7.

Osteoporosis: non-hormonal treatment.

Rizzoli R.

Climacteric. 2007 Oct;10 Suppl 2:74-8.

PMID:
17882678
8.
9.

Osteoporosis screening and risk management.

Wilkins CH.

Clin Interv Aging. 2007;2(3):389-94.

10.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Wensel TM, Iranikhah MM, Wilborn TW.

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Review.

PMID:
21923432
11.

Fracture prevention in postmenopausal osteoporosis: a review of treatment options.

McCarus DC.

Obstet Gynecol Surv. 2006 Jan;61(1):39-50. Review.

PMID:
16359568
12.

Patient treatment preferences for osteoporosis.

Fraenkel L, Gulanski B, Wittink D.

Arthritis Rheum. 2006 Oct 15;55(5):729-35.

13.

Efficacy and safety of currently marketed anti-osteoporosis medications.

Reginster JY, Neuprez A, Dardenne N, Beaudart C, Emonts P, Bruyere O.

Best Pract Res Clin Endocrinol Metab. 2014 Dec;28(6):809-34. doi: 10.1016/j.beem.2014.09.003. Epub 2014 Sep 16. Review.

PMID:
25432354
14.

Considerations regarding adherence of anti-osteoporosis therapy.

Lagari VS, McAninch E, Baim S.

Postgrad Med. 2015 Jan;127(1):92-8. Epub 2014 Dec 15. Review.

PMID:
25526234
15.

Efficacy, effectiveness and side effects of medications used to prevent fractures.

Reid IR.

J Intern Med. 2015 Jun;277(6):690-706. doi: 10.1111/joim.12339. Erratum in: J Intern Med. 2015 Sep;278(3):333.

16.

Drug insight: Existing and emerging therapies for osteoporosis.

Mulder JE, Kolatkar NS, LeBoff MS.

Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):670-80. Review.

PMID:
17143314
17.

Use of bisphosphonates in the management of postmenopausal osteoporosis.

Papapoulos SE.

Ann N Y Acad Sci. 2011 Feb;1218:15-32. doi: 10.1111/j.1749-6632.2010.05767.x. Epub 2010 Sep 29. Review.

PMID:
20946579
18.

The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.

McHorney CA, Schousboe JT, Cline RR, Weiss TW.

Curr Med Res Opin. 2007 Dec;23(12):3137-52. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):707.

PMID:
17988435
19.
20.

Supplemental Content

Support Center